Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 8th International Conference on Tissue Science and Regenerative Medicine Singapore.

Day 1 :

Keynote Forum

Claire Henchcliffe

Weill Cornell Medical Center, USA

Keynote: Regenerative treatments for Parkinson’s disease: How far can stem cells take us?

Time : 09:00-09:40

OMICS International Tissue Science Congress 2017 International Conference Keynote Speaker Claire Henchcliffe photo

Claire Henchcliffe serves as the Director for the Weill Cornell Parkinson’s Disease & Movement Disorders Institute in New York, Vice Chair for Clinical Research and Associate Professor in Neurology, New York at Presbyterian Hospital/Weill Cornell Medical Center, New York, USA. She has completed her Doctorate degree at Oxford University, UK, followed by Post-doctoral Genetics and Neuroscience research at the University of Cambridge, UK and the University of California at Berkeley, USA. She has completed her Medical training at the College of Physicians and Surgeons of Columbia University in New York. She is a Fellow of the American Academy of Neurology and the American Neurological Association and a Member of the Movement Disorders Society and the Parkinson’s Study Group. She has published and lectured widely on Parkinson’s disease.


Rapid advances in stem cell technology have resulted in promise for a neurorestorative approach for treating Parkinson’s disease (PD), a disabling neurodegenerative movement disorder. Parthenogenetic neural progenitor cells are in early clinical testing and several groups, including ours, now seek to examine the effects of transplanting dopamine cells derived from either hESC or iPS cells. In light of these current efforts, it is important to understand outcomes of previous attempts at cell replacement. Previous transplant studies have most commonly focused upon human fetal tissue, although autologous adrenal tissue transplants and retinal pigmented epithelial cells have been tested and will be reviewed. Open label studies of human fetal tissue allotransplantation starting in Lund, Sweden in 1987 paved the way for multiple clinical trials, including two randomized, double blinded, sham surgery controlled clinical trials of bilateral tissue transplant in PD. However, despite this rich history, there is a dearth of data on very long term outcomes. We have therefore examined five surviving participants from the NIH-funded, randomized, double blinded, sham surgery controlled clinical trial of fetal ventral mesencephalic tissue transplant in advanced PD undertaken at the University of Colorado. These patients underwent surgery in 1997-1998 and were examined up to 36 years’ PD duration. Video-recorded motor examinations and Parkinson’s Kinetigraph™ accelerometry-based continuous monitoring demonstrated motor signs consistent with surviving graft tissue as measured by 11C-PE2i PET imaging. In particular, we observed an unexpectedly high level of motor function in two subjects at 28 years and 35 years PD duration. However, non-motor features and non-dopa responsive symptoms were prominent, including sleep disorders, dysautonomia and imbalance. In summary, at very long term follow up 17-18 years post-transplant, there is evidence of graft survival with clinical heterogeneity between subjects likely reflecting heterogeneous graft as well as underlying differences between PD patients.

Keynote Forum

Nadia Benkirane-Jessel

Inserm - French National Institute of Health and Medical Research, France

Keynote: Combined therapeutic medical device and stem cells for regenerative nanomedicine

Time : 09:40-10:20

OMICS International Tissue Science Congress 2017 International Conference Keynote Speaker Nadia Benkirane-Jessel photo

Nadia Benkirane-Jessel is a Research Director and Head of the Osteoarticular and Dental Regenerative Nanomedicine laboratory at INSERM (French National Institute for Health and Medical Research), France. She has received her PhD from University Louis Pasteur, France for the work on development of pseudopeptides as synthetic vaccines. She has then held a Postdoctoral position in collaboration with the Institut Pasteur, France, working on immunotherapy HIV and another Postdoctoral position on the application of modified peptides as vaccines against FMDV (Plum Island Animal Disease Center, ARS, USDA, Greenport, USA). She has joined the INSERM U595 in 2002 as a Post-doctorate and received a Diploma to direct the research (HDR) in 2004. She possesses expertise in diverse fields of molecular and cellular biology, immunochemistry, tissue engineering and biomedical engineering. In the last 10 years, she focused her research on the bio-functionalization of multilayered polyelectrolyte architectures with emphasis on the use of these architectures to induce specific cellular responses and gain control over cell proliferation and differentiation. She has 138 peer-reviewed publications in high impact factor journals, 5 chapter reviews and 5 international patents and is a regular referee for a number of scientific journals.


In our group we explore a new generation of smart living implants combining not only active therapeutics but also stem cells, as a novel strategy to regenerate stabilized cartilage and avoid prosthesis by achieving regeneration of its subchondral bone foundation, requirement which is failing today in the clinic. In our group, a unique nanotechnology strategy is used to entrap, protect and stabilize therapeutic agents into polymer coatings: Nanoreservoirs, covering nanofibers of implantable nanofibrous membranes for bone and cartilage regeneration. Upon contact with cells, therapeutic agents become available through enzymatic degradation of the nanoreservoirs. As cells grow, divide and infiltrate deeper into the porous membrane, they trigger slow and progressive release of therapeutic agents that, in turn, stimulate further cell proliferation. The nanoreservoirs technology enables to reduce the quantities of required therapeutic agent (compared to soaked membranes for instance) thereby reducing costs.

Keynote Forum

Tanongsak Panyawirunroj

Asia Cosmetic Hospital, Thailand

Keynote: Minimal invasive TANONGSAK technique for reduction malarplasty

Time : 10:20-11:00

OMICS International Tissue Science Congress 2017 International Conference Keynote Speaker Tanongsak Panyawirunroj photo

Dr. Tanongsak Panyawirunroj is a Founder, a Chairman, and the principal surgeon at Asia Cosmetic Hospital Thailand, The Best Plastic Surgery in Thailand. Dr. Tanongsak Panyawirunroj specializes in Maxillofacial surgery, Breast augmentation, Face Change – from male to female, Rhinoplasty, Liposuction, Sex Change – from male to female and etc. He has many certifications for various domains such as: micro-vascular surgery, plastic surgery, maxilla-facial surgery, aesthetic surgery and pediatric surgery. The doctor is also a member of the International Society of the Aesthetic Plastic Surgery. Dr. Tanongsak Panyawirunroj never thought of any field other than medicine since childhood. He chose as his Alma Mater the Siriraj Hospital Medical College of Mahidol University (Bangkok, THAILAND). He has earned the degree of Doctor of Medicine in 1998. Furthermore, he has been winning and earning many more awards, trophies and certificates. The latest award was The Best Manager Awards 2015, Medical Sphere (SOCRATES AWARDS  2015)  by Europe Business Assembly. And the recent reputation was being as Honorable speaker and Chairman for Plastic Aesthetic Surgery Conference 2016, Toronto, Canada.



Southeast Asian women prefer oval shape facial contour. To achieve this goal, there are a lot of procedures to reshape the facial skeleton. Reduction malarplasty is a common operation. Although multiple technique have been developed for reduction malarplasty. This study presents a new less invasive TANONGSAK technique for reduction malarplasty.


Between January 2015 and December 2015, we applied TANONGSAK technique for reduction malarplasty in 38 patients. TANONGSAK technique was performed osteotomy site at zygomatic arch with 12 mm in length preauricular incision and at Zygomatic body with 25 mm in length intraoral incision by a reciprocating saw. Out site-in Closed reduction was performed to reposition of malar bone complex. Internal fixation was not required.


The patients were followed up for 5 to 183 days postoperatively (mean 39 days). 94% of patients (36 patients) had satisfactory aesthetic results. The facial contour reduction was accomplished 0.1%-13.79% (mean 2.46%) in size reduction. The operative time in each case was less than 60 minutes. The mean hospital stay was 1.1 day (1-2 day) and patients required recovery period 2-14 days (mean 8.7 days) .2 of patients developed temporary inferior orbital nerve injury. No facial nerve injury and no any other postoperative complications.


Minimal invasive TANONGSAK reduction malarplasty is a preferable technique. This technique provides multiple advantages, including simple manipulation, less invasive, short incision, no internal fixation, good stability, achieved aesthetic results, short operative and recovery time, and less complications.